Page last updated: 2024-09-02

kt 6149 and Bone Marrow Diseases

kt 6149 has been researched along with Bone Marrow Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D1
Ashizawa, T; Gomi, K; Hirata, T; Okabe, M1

Trials

1 trial(s) available for kt 6149 and Bone Marrow Diseases

ArticleYear
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
    Anti-cancer drugs, 1995, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Unknown Primary; Salvage Therapy

1995

Other Studies

1 other study(ies) available for kt 6149 and Bone Marrow Diseases

ArticleYear
Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
    Anti-cancer drugs, 1993, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow Diseases; Colony-Forming Units Assay; Female; Hematopoietic Stem Cells; Lung Diseases; Male; Megakaryocytes; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mitomycin; Mitomycins; Organ Size; Spleen; Tumor Cells, Cultured

1993